102 results about "Carcinoma cell line" patented technology

The invention discloses a nucleic acid aptamer with a sequence containing DNA (deoxyribonucleic acid) segments shown by any of a sequence 1 and a sequence 2. The nucleic acid aptamer can also be derivatives obtained by various similar sequences high in homology or the sequence. The invention further discloses a screening method of the nucleic acid aptamer. The method includes: synthesizing a random single-strand DNA library and a primer, performing Cell-SELEX screening and PCR (polymerase chain reaction) library amplification, preparing a DNA single-strand library, and obtaining the nucleic acid aptamer through repeated screening, negative screening and several rounds of screening. The nucleic acid aptamer and derivatives thereof can be applied to recognizing human biliary duct carcinoma cell line QBC-939 or preparing a reagent box for detecting the human biliary duct carcinoma cell line QBC-939, has affinity and specificity higher than anti-keratin antibodies, and is free of immunogenicity, capable of being chemically synthesized, small in molecular weight, stable, easy to store and mark, and the like.

Adenovirus types 11p and 4p show a higher binding affinity and infectivity than type 5 for endothelial and carcinoma cell lines. Adenovirus type 11p shows a stronger binding to cells for neural origin, such as glioblastoma, neuroblastoma and medulloblastoma. The fact that adenovirus type 11 has a comparatively low prevalence in society, together with its high affinity and infectivity, makes it very suitable for use in gene therapy.

Adenovirus types 11p and 4p show a higher binding affinity and infectivity than type 5 for endothelial and carcinoma cell lines. Adenovirus type 11p shows a stronger binding to cells for neural origin, such as glioblastoma, neuroblastoma and medulloblastoma. The fact that adenovirus type 11 has a comparatively low prevalence in society, together with its high affinity and infectivity, makes it very suitable for use in gene therapy.

The invention belongs to the field of micro-organism animal cell line and relates to a human hepatoma cell line which can emit high-intensity red or green fluorescence and has high transferring ability of lung and lymph node metastasis, and a method for establishing the same. The method comprises the following steps: using the human hepatoma cell line HCCLM3 and HCCLM6 which have high transferring ability of the lung and lymph node metastasis as mother cells, performing cotransfection on plasmid DNA of 239 cells through slow virus packaging plasmids to obtain false slow virus particles by expressing red or green fluorescent protein genes through eucaryon, and infecting liver cancer cell strains of the mother cells to obtain the chromosome integrated hepatoma cell line which has high transferring ability of the lung and lymph node metastasis and can stably expressing the red or the green fluorescence. The human hepatoma cell line which has high transferring ability of the lung and lymph node metastasis in vitro can be applied to the tracer studies on tumor cells, the molecular mechanism studies on the recurrence and transferring of liver cancer, as well as the pre-clinical drug efficacy studies on new anti-tumor drugs, thus the human hepatoma cell line has wide application prospect.

The invention provides a colorectal carcinoma cell line CJF from hepatic metastasis and a construction method thereof. The obtaining method of the colorectal carcinoma cell line comprises the following steps: obtaining tissues of colorectal carcinoma hepatic metastasis; after digesting the tissues into single cells by using collagenase / hyaluronidase, separating and inoculating CD133+ cells under NOD (Non-Obese Diabetic) / SCID rat skin by MACS (magnetic-activated cell separation); nodulating, and taking out tumor tissues; and culturing in vitro to obtain the colorectal carcinoma cell line CJF which can stably passage and is rich in colorectal carcinoma stem cells. In the invention, CJF cells are obtained from hepatic metastasis of colonic carcinoma patients; compared with other colorectal carcinoma cell lines, the colorectal carcinoma cell line CJF has incomparable advantages for the study of the colonic carcinoma hepatic metastases; cell subsets of the CJF cells for stably expressing the CD133+ cells is about 10 percent; and the action and the research of the colorectal carcinoma cell line in a colorectal carcinoma hepatic metastases process and the tumor stem cells in a metastases mechanism have wide application prospects.

The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-κB and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL / lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

Quinoline derivatives showing anticancer activities against cancer cell lines of hepatocellular carcinoma (Hep3B), lung carcinoma (A549), esophageal squamous cell carcinoma (HKESC-1, HKESC-4 and KYSE150). The quinoline derivatives have a backbone structure of the following formulas:

The invention relates to a method for preparing an alkaloidal compound penicillium enol D2 derived from Penicillium citrinum and an application of penicillium enol D2. The compound has an effect of inhibiting proliferation of tumor cells and has antitumor activity. The structural formula is as shown in the specification. The compound is prepared by the steps: performing fermentation cultivation on Penicillium citrinum IBPT-5, and separating and purifying the compound from the fermented product. The experiment proves that the compound has high antitumor activity on the human lung carcinoma cell line A549. The compound can serve as a medicine for inhibiting cell proliferation or an antitumor drug to be used for antitumor research.

The invention provides a human colon carcinoma cell line DXH-1, which is derived from primary lesion of human sigmoid colon carcinoma, and application of the human colon carcinoma cell line as a human colon carcinoma occurrence, human colon carcinoma development or human colon carcinoma transfer cell model, application of the human colon carcinoma cell line in establishing a human colon carcinoma animal model and application of the human colon carcinoma cell line in researching a human colon carcinoma occurrence mechanism and / or medicines for treating the human colon carcinoma. The human colon carcinoma cell line DXH-1 disclosed by the invention can be stably transferred for more than 50 generations, so that an appropriate material is provided for colorectal carcinoma mechanism and drug screening. In an in-vivo nude mice experiment, the human colon carcinoma cell line shows a relatively strong tumorigenesis cavity, and the cell line, transplanted subcutaneously in nude mice by 1*106 cells, is capable of promoting 100% (5 / 5) tumorigenesis after 35 days; the DXH-1 cell has certain drug resistance to colon carcinoma chemotherapeutics (5FU, such as oxaliplatin, irinotecan and the like), so that a material is provided to the researches on a colon carcinoma chemotherapeutic resistance mechanism; and the human colon carcinoma cell line DXH-1 is preserved in China Center for Type Culture Collection in Wuhan University, Wuhan, China with number of CCTCC No: C201543.

Human breast carcinoma SK-BR-3 cell strain as source cell for building train adapted by the invention is continuously inoculated on female NOD / SCID mouse mammary gland fat pad and filtered in pressure of low dose chemotherapy drug tail intravenous injection to build human breast carcinoma cell line SK-3rd rich in tumour breast carcinoma stem cell. The proper of knub stem cell in the cell is increased greatly comparing with non NOD / SCID vivo passage source cell. The formation rate of saccule and the number of cell in the saccule are increased greatly in case of cell suspension culture. The ratio of undifferentiation cancer cell is reduced but is higher evidently than source cell in process of SK-3rd saccule cell inducing differentiation. The saccule cell formed from SK-3rd cell has carcinoma stem cell phenotype which gradually dies out in process of differentiation. NOD / SCID mouse orthotopic transplantation has high tumour-forming rate, high long-distance transferring rate, short tumour-forming periodic time and less number of cells needed by tumour-forming. The invention is an ideal mould for studying breast carcinoma stem cell and has wide applications foreground for disclosing generation mechanism of breast carcinoma and neoplastic treat.

The invention relates to a ferrocene derivative shown as a formula (IA) or a formula (IB) or a pharmaceutically-acceptable salt or a solvate and a medicinal composition thereof. In the formula, R is independently selected from hydrogen, halogen, a cyano-group, a nitro-group, alkyl with 1 to 6 carbon atoms, alkoxy with 1 to 6 carbon atoms, hydroxyl-alkyl with 1 to 6 carbon atoms, halogenated alkyl with 1 to 6 carbon atoms, halogenated alkoxy with 1 to 6 carbon atoms, or alkoxy with 1 to 6 carbon atoms; Z is selected from O, S or NR1; R1 is hydrogen or alkyl with 1 to 6 carbon atoms independently; n is an integer of 0 to 5. The invention further provides a preparation method and medical application of the compound shown as the formula (IA) or the formula (IB) or the pharmaceutically-acceptable salt thereof. The compound has very high restraining activity specific to a lung cancer cell line A549, a colorectal carcinoma cell line HCT116 and / or a breast cancer cell line MCT-7, has broad-spectrum anti-cancer activity, and can be taken as a candidate compound or a lead compound for treating tumor diseases or cancer diseases. The derivative is shown in the description.

The invention discloses an EGFR (epidermal growth factor receptor) TKI (tyrosine kinase inhibitor) BF3-AZD9291 with anti-tumor activity as well as a preparation method and application thereof, and belongs to the field of biomedicines. By optimizing and improving the chemical structure of AZD9291, a fully new EGFR TKI is obtained, and is named as BF3-AZD9291 (formula I). Proofed by study, the synthesized EGFR TKI BF3-AZD9291 has the advantages that the drug resistance of tumor cells can be effectively inhibited; compared with AZD9291, the stronger drug resistance inhibiting function is realizedfor the mutation EGFR tumor cell line H1975T790M, and the EGFR TKI BF3-AZD9291 can be used as an anti-tumor reagent in clinical application. The invention also discloses the method for preparing theEGFR TKI BF3-AZD9291 with the anti-tumor activity. The EGFR TKI BF3-AZD9291 provides an effective technical method for the treatment of tumors, especially non-small cell lung cancer. (The formula I isshown in the attached figure.).